Literature DB >> 8233392

Visual acuity in patients with best vitelliform macular dystrophy.

G A Fishman1, W Baca, K R Alexander, D J Derlacki, A M Glenn, M Viana.   

Abstract

PURPOSE: Forty-seven patients with Best vitelliform macular dystrophy were evaluated in a cross-sectional fashion for visual acuity loss with age.
METHODS: The authors assessed only patients who had at least one eye with a recognizable phenotype of Best vitelliform macular dystrophy. Patients with absent foveal changes or with only minimal foveal pigment mottling and hypopigmentation in each eye were excluded.
RESULTS: A significant difference was noted between the visual acuities of the two eyes of the patients (2 lines or greater in the majority [64%] of patients). Nevertheless, for both eyes a significant correlation was noted between patient age and visual acuity, with older patients tending to have worse visual acuities. In the eyes with the best visual acuity, the majority of patients younger than 40 years of age (76%) had a visual acuity of 20/40 or better. In patients older than 30 years of age, a substantial percentage (74%) had a visual acuity of 20/100 or worse in at least one eye.
CONCLUSION: The authors' findings indicate that although patients with Best vitelliform macular dystrophy who show characteristic macular lesions may retain good visual acuity in at least one eye, an appreciable number can lose substantial visual acuity, at least monocularly. In this population, no patient older than 50 years of age fulfilled the visual acuity criterion of 20/40 in at least one eye, the requirement in most states for an unrestricted driver's license, and only 20% of patients older than 40 years of age fulfilled this visual acuity criterion.

Entities:  

Mesh:

Year:  1993        PMID: 8233392     DOI: 10.1016/s0161-6420(93)31420-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

1.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

2.  Multimodal imaging of adult-onset foveomacular vitelliform dystrophy.

Authors:  Seanna Grob; Yoshihiro Yonekawa; Dean Eliott
Journal:  Saudi J Ophthalmol       Date:  2014-04

Review 3.  Molecular genetics of macular degeneration.

Authors:  M A Musarella
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

Review 4.  Diagnosis and classification of macular degenerations: an approach based on retinal function testing.

Authors:  L Scullica; B Falsini
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

Review 5.  Genotype-phenotype correlations and differential diagnosis in autosomal dominant macular disease.

Authors:  A Iannaccone
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

6.  Three-dimensional distribution of the vitelliform lesion, photoreceptors, and retinal pigment epithelium in the macula of patients with best vitelliform macular dystrophy.

Authors:  Christine N Kay; Michael D Abramoff; Robert F Mullins; Tyson R Kinnick; Kyuongmoo Lee; Mari E Eyestone; Mina M Chung; Elliott H Sohn; Edwin M Stone
Journal:  Arch Ophthalmol       Date:  2011-11-14

7.  Pattern ERG and psychophysical functions in Best's disease.

Authors:  M Jarc-Vidmar; P Popović; M Hawlina; J Brecelj
Journal:  Doc Ophthalmol       Date:  2001-07       Impact factor: 2.379

Review 8.  Functional roles of bestrophins in ocular epithelia.

Authors:  Alan D Marmorstein; Harold E Cross; Neal S Peachey
Journal:  Prog Retin Eye Res       Date:  2009-05-04       Impact factor: 21.198

9.  Outer retinal structure in best vitelliform macular dystrophy.

Authors:  David B Kay; Megan E Land; Robert F Cooper; Adam M Dubis; Pooja Godara; Alfredo Dubra; Joseph Carroll; Kimberly E Stepien
Journal:  JAMA Ophthalmol       Date:  2013-09       Impact factor: 7.389

10.  N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population.

Authors:  Mark A Babizhayev; Leslie Burke; Philip Micans; Stuart P Richer
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.